Teva’s biosimilar development expertise is set to increase with its latest joint venture with Swiss company, Lonza. The two companies will work together in developing and manufacturing biosimilars – whose market size is expected to surge under the new US administration. However, some big pharma companies are also making moves into the sector, thus providing Teva with stiff competition.